Eckert & Ziegler Becomes European Contract Manufacturer for Telix's Phase III ProstACT GLOBAL Study

Berlin, August 13, 2024 - Eckert & Ziegler has secured a multi-year agreement to act as the European contract manufacturing organization (CMO) for Telix Pharmaceuticals’ ProstACT GLOBAL Phase III study. This collaboration involves supplying the entire European patient base from their Berlin facility. Additionally, Eckert & Ziegler will provide high-purity, GMP-grade Lutetium-177 (Lu-177), a critical starting material.

Telix’s study investigates Lutetium (Lu 177) rosopatamab tetraxetan, a radio-labeled antibody drug conjugate (rADC), in adult males with PSMA-positive prostate cancer. "We are happy to further expand our collaboration with Telix," said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE.

Darren Patti, Group COO of Telix, emphasized the partnership’s potential impact on the study's success, citing Eckert & Ziegler’s expertise and facility quality. This step aligns with both companies' dedication to advancing radiopharmaceutical solutions. Eckert & Ziegler offers a broad range of services from early development to distribution.